Anthropic is getting into the business of inventing medicines. On Tuesday, at an event in San Francisco, the artificial-intelligence company announced it will launch its own internal drug discovery program while introducing a new research platform called Claude Science for drugmakers, scientists and universities.

Eric Kauderer-Abrams, Anthropic’s head of life sciences, said the company’s in-house effort will focus on “neglected” diseases—conditions that traditional pharmaceutical companies often overlook because they offer limited commercial returns. He said the internal program is designed to give Anthropic firsthand experience developing medicines while improving the AI tools it sells to the biopharmaceutical industry.

The company’s larger commercial push is Claude Science, a version of its Claude AI models designed specifically for scientific research rather than general conversation. The platform integrates scientific databases, computing resources and specialized tools for genomics, proteomics and drug discovery. Available in beta for Pro, Max, Team and Enterprise users on macOS and Linux, it can analyze large research datasets, review scientific literature, interpret biological data and visualize three-dimensional protein structures—an essential part of modern drug development.

The strategy is straightforward: provide advanced AI tools to researchers searching for new medicines. Bringing a drug from discovery to market typically takes more than a decade and costs billions of dollars, with much of that time spent identifying and testing potential drug candidates before they ever reach clinical trials. Anthropic believes software that accelerates those early stages could become valuable to an industry that already invests heavily in research and development.

To earn credibility, the company says it wants direct experience in the work itself. Jonah Cool, Anthropic’s head of life sciences partnerships, said the neglected-disease initiative will complement the company’s commercial AI business, arguing that building better scientific tools requires understanding researchers’ day-to-day challenges. Anthropic also announced a support program that will provide up to 50 research projects with as much as $30,000 each in computing credits.

The move builds on a broader healthcare strategy. Anthropic launched its AI for Science initiative in 2025, followed by Claude for Life Sciences later that year and Claude for Healthcare in early 2026. In April 2026, the company acquired biotech startup Coefficient Bio in a stock deal reportedly valued at roughly $400 million, bringing additional drug-discovery expertise in-house. Anthropic has also partnered with major pharmaceutical companies including Novo Nordisk, AstraZeneca and Eli Lilly, which use Claude for literature reviews, clinical documentation and regulatory work.

Anthropic is entering a competitive field. Technology companies including Alphabet, Apple and Amazon have all pursued healthcare initiatives with varying degrees of success. In scientific research, Alphabet’s DeepMind transformed biology with AlphaFold, which predicts the three-dimensional structures of proteins, while AI-focused biotechnology companies such as Recursion and Exscientia have formed partnerships with major pharmaceutical firms. OpenAI has also expanded its efforts in scientific research.

Even so, significant challenges remain. Healthcare has historically proven difficult for technology companies, and developing reliable scientific tools requires far greater precision than consumer AI applications. Kauderer-Abrams did not specify what Anthropic would do if its internal research identifies a promising drug candidate. Advancing such discoveries through clinical trials is an expensive, highly regulated process that the company has not previously undertaken.

Researchers also caution that AI-generated findings should always be independently validated before being used in scientific studies or drug development. Others have questioned whether advanced AI tools available through premium subscriptions could widen the gap between well-funded research institutions and smaller organizations, although Anthropic says it plans to offer expanded access programs for nonprofits and universities.

For Anthropic, the opportunity is substantial. Expanding into healthcare diversifies revenue beyond consumer AI products and positions the company within an industry that spends hundreds of billions of dollars annually on research and development. Industry analysts said Tuesday’s announcements reflect Anthropic’s broader strategy of building long-term enterprise revenue through specialized AI products.

Whether that strategy succeeds will take years to determine. Drug discovery rewards patience more than speed, and the ultimate measure of Claude Science will not be how quickly it analyzes research papers, but whether it helps scientists develop medicines that ultimately improve patients’ lives.

JBizNews Desk
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.